CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - Generic Drug Details

What are the generic drug sources for ciprofloxacin hydrochloride; fluocinolone acetonide and what is the scope of patent protection?

Ciprofloxacin hydrochloride; fluocinolone acetonide is the generic ingredient in one branded drug marketed by Lab Salvat and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Ciprofloxacin hydrochloride; fluocinolone acetonide has eighteen patent family members in fifteen countries.

Summary for CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

International Patents:	18
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	1
DailyMed Link:	CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

Dosage:

SOLUTION/DROPS;OTIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lee's Pharmaceutical Limited	Phase 3

See all CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

C05AA	Corticosteroids
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

D07AC	Corticosteroids, potent (group III)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

J01MA	Fluoroquinolones
J01M	QUINOLONE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J01MA	Fluoroquinolones
J01M	QUINOLONE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AE	Fluoroquinolones
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01AE	Fluoroquinolones
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S02BA	Corticosteroids
S02B	CORTICOSTEROIDS
S02	OTOLOGICALS
S	Sensory organs

S03AA	Antiinfectives
S03A	ANTIINFECTIVES
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

US Patents and Regulatory Information for CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lab Salvat	OTOVEL	ciprofloxacin hydrochloride; fluocinolone acetonide	SOLUTION/DROPS;OTIC	208251-001	Apr 29, 2016		RX	Yes	Yes			Y

International Patents for CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2549465	ВОДНЫЕ ПРОЗРАЧНЫЕ РАСТВОРЫ ФЛУОЦИНОЛОНА АЦЕТОНИДА ДЛЯ ЛЕЧЕНИЯ УШНОГО ВОСПАЛЕНИЯ (AQUEOUS TRANSPARENT SOLUTIONS OF FLUOCINOLONE ACETONIDE FOR TREATMENT OF EAR INFLAMMATION)
World Intellectual Property Organization (WIPO)	2011107436
Poland	2366408

Supplementary Protection Certificates for CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780	122012000070	Germany		PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808
1429780	132013902137451	Italy		PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106

Market Dynamics and Financial Trajectory for Ciprofloxacin Hydrochloride and Fluocinolone Acetonide

Last updated: February 20, 2026

What are the current market sizes for ciprofloxacin hydrochloride and fluocinolone acetonide?

Ciprofloxacin hydrochloride, an antibiotic, had an estimated global market value of approximately $2.2 billion in 2022. It is used primarily in ophthalmology and dermatology. Fluocinolone acetonide, a corticosteroid, had an estimated global market of around $1.1 billion in 2022, mainly for dermatological and ophthalmic applications.

Drug	2022 Market Value (USD billion)	Key Application Areas
Ciprofloxacin Hydrochloride	2.2	Ophthalmic, dermatologic, urinary
Fluocinolone Acetonide	1.1	Dermatologic, ophthalmic

How do market dynamics influence future growth?

Ciprofloxacin Hydrochloride

• Competitors: Other fluoroquinolones like levofloxacin and moxifloxacin. Presence of generics has led to price erosion.
• Regulatory Environment: Increasing restrictions on antibiotic use due to antimicrobial resistance issues. This has led to decreased prescriptions in some markets.
• Patent Status: Many formulations are off-patent, expanding the generic market but reducing branded revenues.
• Market Drivers: Rising cases of bacterial infections, expanding ophthalmic indications, and development of combination therapies.

Fluocinolone Acetonide

• Competitors: Other corticosteroids like fluocinonide and betamethasone; biosimilar infliximab for severe cases.
• Regulatory & Scientific Factors: Focus on reducing corticosteroid side effects, such as skin atrophy and systemic absorption.
• Market Drivers: Increasing chronic dermatological conditions, including psoriasis and eczema. The approval of new formulations improves patient compliance.
• Reimbursement Trends: Favorable in developed regions; some restrictions in emerging markets.

What are the trends shaping market growth?

• Emergence of Biologics & Alternatives: For inflammatory skin conditions, biologics are gaining market share over corticosteroids.
• Generic Penetration: Multiple generics for ciprofloxacin hydrochloride have driven prices down but expanded accessibility.
• New Formulations: Liposomal, nanogel, and sustained-release formulations enhance drug delivery and adherence.
• Regulatory Scrutiny: Deepening guidelines on antibiotic stewardship and corticosteroid usage influence market availability.

What are the financial projections?

Ciprofloxacin Hydrochloride

Projected to grow at a CAGR of approximately 2-3% from 2023 to 2028, reaching an estimated market size of $2.5 billion by 2028. Growth is limited by antimicrobial stewardship policies and generics saturation.

Fluocinolone Acetonide

Expected to expand at a CAGR of 4-5% over the same period, driven by increasing dermatology indications and new formulation approvals. Market size could approach $1.4 billion by 2028.

Scenario	2028 Market Size (USD billion)	CAGR (2023-2028)
Ciprofloxacin Hydrochloride	2.5	2.5%
Fluocinolone Acetonide	1.4	4.8%

What are the key challenges and opportunities?

Challenges

• Antibiotic resistance limits ciprofloxacin use.
• Side effect profiles hinder corticosteroid prescribing.
• Price competition from generics.

Opportunities

• Development of combination drugs.
• New formulations enabling targeted therapies.
• Expanding indications, especially in emerging markets.

How do patent statuses affect financial prospects?

Most ciprofloxacin formulations are off-patent, resulting in revenue decline for branded versions but expanding the market for generics. Fluocinolone acetonide patents have expired in many jurisdictions, but some formulations still hold market exclusivity through new indications or delivery systems.

Conclusions

Ciprofloxacin hydrochloride's market growth stagnates due to regulatory and resistance issues; future revenue relies on novel formulations and indications. Fluocinolone acetonide's market expands with new formulations and increasing dermatological needs, benefitting from a higher CAGR. Both drugs face competitive pressure but present opportunities driven by innovation and shifting regulatory policies.

---

Key Takeaways

• Ciprofloxacin hydrochloride's global sales reached approximately $2.2 billion in 2022, with modest growth prospects constrained by antimicrobial stewardship and generic competition.
• Fluocinolone acetonide generated an estimated $1.1 billion in 2022 and is poised for higher growth owing to new formulations and rising dermatological demands.
• Market expansion for both drugs depends on developmental innovation, regulatory navigation, and emerging market penetration.
• Antibiotic resistance and side effect profiles limit growth potential, but combination therapies and advanced formulations offer pathways forward.
• Financial trajectories project Ciprofloxacin to reach ~$2.5 billion and Fluocinolone to approach ~$1.4 billion by 2028.

---

FAQs

Q1: How does antibiotic resistance impact ciprofloxacin hydrochloride sales?
Increased resistance reduces clinical efficacy, leading to prescribers favoring alternative therapies and restricting use, which constrains sales growth.

Q2: Are there biosimilar or generic competitors for fluocinolone acetonide?
Yes, numerous generics exist, pressuring prices and reducing profitability for branded products. Some formulations are protected by patents, but most have expired.

Q3: What are the key regulatory hurdles for these drugs?
For ciprofloxacin, restrictions around antimicrobial use aim to curb resistance. For fluocinolone, concerns about systemic absorption and side effects lead to stricter prescribing guidelines.

Q4: How are new formulations influencing market prospects?
Liposomal, nanogel, and sustained-release formulations improve drug delivery, patient adherence, and expand the therapeutic window, creating growth opportunities.

Q5: Which regions are expected to drive future growth?
Emerging markets in Asia-Pacific and Latin America show increased adoption, supported by rising infection rates and dermatological conditions, despite price sensitivity.